** Shares of Florida-based drug developer MIRA Pharmaceuticals MIRA.O fall 8.6% to $1.17 premarket

** Agrees to buy privately held Delaware-based SKNY Pharmaceuticals in a stock deal to add experimental weight-loss drug candidate - regulatory filing

** SKNY-1 is an experimental oral drug in preclinical development for weight-loss and smoking cessation

** Says SKNY will contribute $5 million in cash or assets at close

** MIRA marginally up in the past 12 months

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))